Immuneering Corporation announced on February 6, 2025, a clinical supply agreement with Regeneron Pharmaceuticals. This agreement facilitates the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Regeneron’s Libtayo (cemiplimab).
The planned evaluation will take place in patients with advanced non-small cell lung cancer (NSCLC) as part of Immuneering's ongoing Phase 2a trial. This collaboration aims to explore the synergistic potential of IMM-1-104, a Deep Cyclic Inhibitor, with an anti-PD-1 therapy.
Preclinical data presented at AACR 2023 supports the dual-targeting potential of IMM-1-104 in combination with anti-PD-1 agents. This partnership represents a strategic move to broaden IMM-1-104's potential indications and leverage external resources for clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.